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RepeatabilityA comprehensive aquatic environmental risk assessment (ERA) of the human pharmaceutical propranolol was
conducted, based on all available scientific literature. Over 200 papers provided information on environmental
concentrations (77 of which provided river concentrations) and 98 dealt with potential environmental effects.
The median concentration of propranolol in rivers was 7.1 ng/L (range of median values of individual studies
0.07 to 89 ng/L), and the highest individual valuewas 590 ng/L. Sixty-eight EC50 values for 35 specieswere avail-
able. The lowest EC50 value was 0.084 mg/L. A species sensitivity distribution (SSD) provided an HC50 value of
6.64 mg/L and an HC5 value of 0.22 mg/L. Thus, there was a difference of nearly 6 orders of magnitude between
the median river concentration and the HC50 value, and over 4 orders of magnitude between the median river
concentration and the HC5 value. Even if an assessment factor of 100 was applied to the HC5 value, to provide
considerable protection to all species, the safety margin is over 100-fold. However, nearly half of all papers
reporting effects of propranolol did not provide an EC50 value. Some reported that very low concentrations of
propranolol caused effects. The lowest concentration reported to cause an effect - in fact, a range of biochemical
and physiological effects on mussels - was 0.3 ng/L. In none of these ‘low concentration’ papers was a sigmoidal
concentration-response relationship obtained. Although inclusion of data from these papers in the ERA cause a
change in the conclusion reached, we are sceptical of the repeatability of these ‘low concentration’ results. We
conclude that concentrations of propranolol present currently in rivers throughout the world do not constitute
a risk to aquatic organisms. We discuss the need to improve the quality of ecotoxicology research so that more
robust ERAs acceptable to all stakeholders can be completed.
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).ealth and Societies, Brunel University London, Uxbridge, Middlesex UB8 3PH, United Kingdom.
ter).
B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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For the last two decades there has been significant concern about the
impact of pharmaceuticals present in the environment on both inverte-
brate and vertebrate wildlife (Fent et al., 2006; Arnold et al., 2014). The
greatest concern exist for aquatic species, because the aquatic environ-
ment probably contains the highest concentrations of human pharma-
ceuticals, as a consequence of their incomplete removal in wastewater
treatment plants (Gardner et al., 2012; Falås et al., 2016) and hence pres-
ence in effluents that are discharged into rivers. In general, concentra-
tions of individual pharmaceuticals in rivers are reported to be low: low
ng/L concentrations are typical (Hughes et al., 2013; Weber et al.,
2015), although in a few unique situations they might reach higher con-
centrations (e.g. Larsson, 2014). Intuitively these low concentrations
might suggest that there is little, if anything, to be concerned about.
However, although it is probably true that relatively few pharmaceuticals
do pose a significant risk to aquatic organisms, some of those that
bioconcentrate in organisms might reach internal concentrations high
enough to cause effects. This seems to be the case with some of the syn-
thetic sex steroid hormones, which can adversely affect reproduction of
fish when present in the surrounding water at extremely low concentra-
tions, even concentrations below 1 ng/L (e.g. Caldwell et al., 2012;
Runnalls et al., 2013; Zeilinger et al., 2009). This realisation has led to
some of the synthetic steroidal pharmaceuticals being considered the
pharmaceuticals of highest risk to aquatic organisms (Runnalls et al.,
2010; Caldwell et al., 2012; Gunnarsson et al., 2019).
One pharmaceutical that has received considerable attention from
both environmental chemists and environmental toxicologists is the
beta-blocker propranolol. This drug often features relatively high up in
lists of pharmaceuticals considered to represent a significant risk to
the environment (e.g. Roos et al., 2012). In fact, Donnachie et al.
(2016) reported that propranolol features very often in prioritization
articles in the literature. This conclusion has been reached on the basis
that propranolol has been detected very often and geographically very
widely in effluents of wastewater treatment works (WWTWs), and
hence also in receiving rivers, and that some papers have reported
adverse effects of extremely low concentrations of the drug on a
number of species of aquatic organisms (see later for specific
references).
Propranolol is used mainly to treat high blood pressure (hyperten-
sion) and angina, although it is also prescribed for a wide variety of
other adverse health conditions, such as migraine and some psychiatric
conditions. In addition to the formally approved therapies, propranolol
is known to be prescribed ‘off-label’ by doctors; that is, for a range of
conditions that the doctor considers it may be appropriate and provide
benefit. It is also used by musicians, actors and public speakers for its
ability to treat anxiety symptoms, and as a performance-enhancing
drug in sport where high accuracy is required. British scientist Sir
James W. Black developed propranolol in the 1960s. It was patented in
1962 and approved for medical use in 1964. It was the first beta-
blocker used effectively in the treatment of coronary artery disease
and hypertension. It is on theWorld Health Organisation's List of Essen-
tial Medicines. Although it is steadily being replaced by newer, more
cardio-selective beta-blockers, such as bisoprolol and metoprolol, it is
still used extensively. In 2017 it was the 41st most commonly pre-
scribed medicine in the United States, with more than 17 million
prescriptions.
The pharmacodynamics of any drug are highly relevant to any
effects they might cause to organisms when they are present in the en-
vironment (Rand-Weaver et al., 2013). Propranolol is a non-selective β-
adrenergic receptor antagonist, or beta-blocker; that is, it blocks the
action of adrenaline (epinephrine) and noradrenaline (norepinephrine)
at both β1 and β2-adrenergic receptors. It is also a weak, indirect α1-
adrenoreceptor agonist, in addition to its potentβ-adrenoreceptor antag-
onism. These molecular targets of propranolol - the α and β-adrenergic
receptors - are highly conserved (Gunnarsson et al., 2008), being present2
throughout the animal kingdom, including in unicellular organisms.
However the distribution and functionality of these receptors varies
(Owen et al., 2007). This has been recognised for decades by comparative
physiologists who have, for example, used propranolol to block β-
adrenergic activity when investigating the control of the heart of lower
vertebrates, particularly fish (e.g. Keen et al., 1995; Tirri and Lehto,
1984). Given the presence of the drug's target in a wide spectrum of or-
ganisms, it was perhaps understandable that there was concern about
the presence of propranolol in the environment causing adverse effects
on exposed organisms.
Based on the current continuing interests, from both scientists and
regulators, on pharmaceuticals in the environment, and the fact that
propranolol has been one of the most widely studied drugs by both en-
vironmental chemists and environmental toxicologists, we considered
that it would be instructive to conduct an environmental risk assess-
ment on propranolol, utilising all available literature. Regulatory envi-
ronmental risk assessments are now conducted as medicines are
registered in many regions of the world. However, those utilise pre-
dicted environmental concentrations based on the epidemiology and
potential use and compare those concentrations to effects generated
in standard tests. In contrast, our risk assessment presented here uses
the open scientific literature. The originality of our approach lies in the
fact that we utilised the entire open scientific literature on the environ-
mental presence and effects of propranolol: over 640 papers were ex-
amined. In contrast, other environmental risk assessments of
pharmaceuticals, or any chemical for that matter, have utilised very
much smaller datasets (e.g. Straub, 2009, 2017), usually because the au-
thor(s) have followed regulatory guidelines on how to conduct environ-
mental risk assessments of chemicals. However, the open scientific
literature is very much more variable and expansive. To provide just
one example of why, research scientists will often use species that
they are interested in, and familiar with, in toxicity tests, rather than
use the limited range of species recommended by regulatory authori-
ties, such as the OECD. Thus, the uniqueness of this paper lies in the
fact that it utilises all relevant scientific literature, making it currently
probably the most thorough and comprehensive risk assessment of
any human pharmaceutical. It highlights many of the problems associ-
ated with regulatory decision making when it comes to deciding
whether or not any particular pharmaceutical poses an unacceptable
risk to the environment.
2. Materials and methods
2.1. Literature searching
The main source of relevant literature was the Web of Knowledge
(WoK) Core Collection of journals. This was searched using a wide vari-
ety of search terms in late February and early March 2017. The search
terms used are listed in Supplementary Information Table S1. The
WoK searches for specified key search words (e.g. propranolol) in the
title or abstract or keywords of scientific papers. In order not to limit
our searching, we conducted multiple searches, based mostly on pairs
of key words (e.g. propranolol and fish) rather than conduct one large
search. This produced a lot of duplication, as expected, yet almost
every individual search provided one or more references that were
not included in any of the other searches. The US EPA Ecotox database
(www.epa.gov/chemical-research/ecotoxicology-database) was also
searched using the key word propranolol. This produced 44 references,
most of which had been captured in the WoK searches.
Based on these searches, an initial list of 1100 papers was compiled.
It was obvious from the titles of these papers that some were not rele-
vant to an environmental risk assessment of propranolol. Based on the
titles of the papers, a master list of 596 papers that could be relevant
was compiled. To assess if it was appropriate to remove just over 500
papers from the initial list, a random sample of 25 of those papers was
read; all proved to be irrelevant, thus justifying their exclusion.
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pers, finding over 200. Themajority of those papers were in the list cre-
ated from theWoK searches, but some 45were not. Those thatwere not
often had phrases such as “selected pharmaceuticals” or “multi-residue
analysis of pharmaceuticals” in their titles, but propranolol was not spe-
cifically mentioned until the Results sections of the papers. These addi-
tional 45 references were added to themaster list, making it a list of 641
papers likely to be of relevance.
All 641 papers were then read in full, enabling their relevance to be
determined. Only papers containing novel data on eithermeasured con-
centrations of propranolol in the aquatic environment (but including at
this stage influent and effluent from WWTWs) or concentrations caus-
ing effects on aquatic organisms (including all organisms and all end-
points) were considered relevant to the risk assessment.
Limited, selective, literature searching was conducted to determine
if river concentrations had changed since the end of the main literature
search conducted in early 2017. Details can be found in Section 2.8.
2.2. Environmental concentrations
There were 211 papers dealing with environmental concentrations
(exposure) amongst the 641 papers considered to be of potential rele-
vance. About half of these papers provided river concentrations; the
rest provided only WWTW influent and/or effluent concentrations
(about 30% of the papers), hospital wastewater concentrations (10%),
estuary concentrations (5%), groundwater (5%) or marine concentra-
tions (5%).Marine concentrationswere excluded fromsubsequent anal-
yses on the basis that they were likely to be lower than river
concentrations. Estuary concentrations were also excluded because
they originated anywhere from the mouth of the estuary (i.e. were al-
most 100% seawater) to 20 Km upstream (almost, but not quite, 100%
freshwater). Data from hospital wastewater was also excluded on the
basis that this wastewater usually goes to a conventional municipal
WWTW before the latter discharges its effluent into rivers. In contrast,
data from freshwater lakes was included in all analyses. These freshwa-
ter lakes were fed by rivers; often rivers receiving WWTW effluent.
Some received WWTW effluent directly. The lakes varied in size;
some were very large, especially some in China. These lakes all
contained populations of aquatic organisms (e.g. fish), and thus were
considered relevant from an environmental risk assessment perspec-
tive. Despite not utilising reported propranolol concentrations in the
marine environment, estuaries, and groundwater, for completeness
these are reported in the Supplementary Information (Table S2).
Seventy-seven (77) papers provided novel, quantifiable river con-
centrations of propranolol (i.e. data not reported in any other paper);
these papers are listed in Table S3. Some of these papers provided
only one single concentration (because only one sample was collected
and analysed), whereas other papers provided information on tens,
and very occasionally over one hundred, river water samples. A few pa-
pers did not state howmany samples were analysed. About three quar-
ters of the papers provided numerical concentrations (i.e. individual
numbers, usually in tables), but one quarter provided data in figures
only. In the latter case we estimated the numerical concentrations
from the figures.
2.3. Dealing with the limit of quantification (LOQ) issue
Most papers provided limits of quantification (LOQ), but some did
not do so. There were 12 papers in which river concentrations were
measured but all samples had concentrations below the LOQ; these pa-
pers are listed in Table S4. However, in the majority of papers some
samples had concentrations below the LOQ, whereas other samples
had measurable concentrations. When the latter situation occurred, it
was often not specified how many samples had concentrations below
the LOQ; only the data for samples with measurable concentrations
were provided. It seems that most authors excluded the samples with3
concentrations below their LOQ when calculating mean/median con-
centrations. Thus, they determined and reported the mean and/or me-
dian concentration of only those samples that had quantifiable
propranolol concentrations. Doing so introduces a positive bias, of
course, but we could not correct that bias because the papers usually
did not contain the information needed to do so.
We are sympathetic to the situationmany authors found themselves
in, because it is very difficult to know how to deal with the ‘non-de-
tects’: those samples with propranolol concentrations below the LOQ.
A variety of approaches are possible, including ignoring them, treating
them as zeros when determining means or medians, assigning to all
samples with concentrations below the LOQ a value half way between
zero and the LOQ (i.e. if the LOQwas 4, assign a value of 2), or assigning
to all samples with concentrations below the LOQ the LOQ value (i.e. 4
in the example above). As far as we can judge, all approaches had
been adopted in the literature from which we extracted environmental
propranolol concentrations. As recently discussed (Hites, 2019), there is
no generally accepted way of dealing with the limit of detection (LOD/
LOQ) issue. We chose to use an approach that utilised all the data avail-
able to us, rather than omit any of them from our analyses.
2.4. Dealing with the chirality issue
Propranolol is chiral; it consists of a 50/50 racemic mixture of R(+)
and S(−) enantiomers, and the S enantiomer is considered the beta-
blocker (100× potency of the R). Six papers separately measured con-
centrations of these two propranolol enantiomers, and hence provided
the concentrations of each one. In two of these papers the sum of the
two enantiomers was also provided. When this was not done by au-
thors, we added together the concentrations of the two enantiomers
to obtain a ‘propranolol concentration’.
2.5. Calculating a representative concentration
The number of samples analysed by the 77 studies providing quan-
tifiable concentrations of propranolol in the freshwater environment
ranged from 1 to 154 (Table S3). It is not possible to provide the exact
number of samples in this category for a number of reasons, including
that some studies did not provide the number of samples analysed
and other studies provided the number of samples analysed but not
the number that had quantifiable concentrations above the LOQ. With
these caveats in mind, we estimate that the number of samples with
measurable concentrations was around 1700.
Most studies provided median concentrations of the samples
analysed, although some provided mean concentrations. To obtain a
representative freshwater propranolol concentration we aggregated
the medians by determining the median of the individual medians:
this is an acceptable meta-analysis approach (McGrath et al., 2019).
Hence we did not incorporate the study-specific, and very variable,
sample size into our analysis. Doing so would have introduced a strong
bias towards those studies that analysed high numbers of samples. In-
stead, each studywas equally weighted in our calculation of a represen-
tative freshwater propranolol concentration.
2.6. Effect concentrations
Out of the master set of 641 papers, 98 were categorised as dealing
with a potential environmental effect of propranolol on any aquatic or-
ganism. In addition, over 60 papers dealt with the role of adrenaline/
noradrenaline in a wide range of physiological processes in a variety
of species. In those studies propranolol was used to block the normal
physiological responses to endogenous adrenaline/noradrenaline,
thereby determining the roles of these catecholamines. The physiologi-
cal processes studied in these laboratory studies included control of the
cardiovascular system, reproduction, colour change, release of hor-
mones from endocrine glands, and stress. Usually only one, very high,
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studies, because the aim was to block completely the effects of endoge-
nous adrenaline/noradrenaline. Thus these studieswere not of use as far
as determining the potential effects of propranolol on freshwater spe-
cies present in the natural environment, and as a consequence they
were excluded from this environmental risk assessment.
Out of the 98 potentially useful papers, 8 were based solely on the
use of various cell lines or primary cells; these were excluded from
subsequent analyses. A few of the 98 papers repeated results that had
previously been reported. Forty-two (42) papers contained EC50 values,
and hence were used in the construction of a species sensitivity distri-
bution (SSD; see below). However, some papers duplicated results
already published; 35 papers provided unique EC50 values. A further
26 papers reported statistically significant effects of propranolol, but
from which an EC50 value could not be obtained (Table S5). There
were a number of reasons for his, the major two being that only one
concentration of propranolol was tested and that a non-sigmoidal
concentration-response relationship was reported. Results from those
26 papers could not be incorporated into a SSD, but were used and
displayed by us here in other types of presentation of the effect concen-
trations. Thirteen (13) of the papers covering environmental effects of
propranolol reported that no effects occurred, and in two papers it
was unclearwhether or not any effects had occurred.We have included
all effect data obtained from laboratory studies utilising marine species
(e.g. mussels) because there is a considerable amount of them and be-
cause much of those data appear to suggest that effects can occur at
very low concentrations of propranolol, and hence excluding those
data might introduce bias into our analysis.
2.7. Presentation of the data
Two approaches to displaying the data were adopted. The most
widely utilised methodology is to create a Species Sensitivity Distribu-
tion (SSD). A SSD is a probability distribution describing the sensitivity
of multiple species to a hazardous compound, in this case the human
pharmaceutical propranolol. To create the SSD we used the executable
tool ETX, access to which was kindly provided by Professor Leo
Posthuma of RIVA, The Netherlands (see also Posthuma and De Zwart,
2014). The second approach was developed recently by Donnachie
and her co-workers. It allows both environmental concentrations and
effect concentrations of a chemical to be displayed in a single figure
(see, for example, Donnachie et al., 2016). Whereas SSDs are based
solely on EC50 values, the methodology developed by Donnachie and
colleagues is more flexible, and can also incorporate all reported effect
concentrations, not only EC50 values.
2.8. Recent information on environmental concentrations of propranolol
Themain literature searcheswere conducted in early 2017. Todeter-
mine whether or not the results derived from that literature are still
valid today, reported concentrations of propranolol in rivers were ob-
tained from recently published papers. A comprehensive literature
search for relevant papers published between 2017 and 2020 was not
conducted; instead, ten recently published papers providing informa-
tion on concentrations of propranolol in rivers, each based on large sam-
pling programmes, were randomly selected (Table S6) and the relevant
information extracted from them.
3. Results
3.1. River concentrations of propranolol
Concentrations of propranolol in riverswere available from20 coun-
tries, with Spain, in particular, and France being the most represented.
Well over half of all data came fromWestern European countries. No in-
formation was available from Africa (but see below for recent4
information) or the Middle East, and very little was available from
South American countries (one study only).
The median concentration of propranolol in rivers was 7.1 ng/L. The
range of the 77 median/mean values of individual studies was 0.07 to
89 ng/L. Only 9 papers reported any individual river water samples
with concentrations above 100 ng/L. The highest single sample concen-
tration was 590 ng/L.
3.2. Concentrations of propranolol causing effects
A significant proportion of the available data did not come from
standardised toxicity tests, such as those recommended by the OECD.
Ideally, acute and chronic toxicity data would have been separated,
and analysed separately. However, doing so was problematic for two
reasons. One was that relatively few authors stated whether the tests
they conducted were considered acute or chronic. The other was that
there is no agreed position on what constitutes acute toxicity and
what constitutes chronic toxicity. This problem is illustrated in the gen-
erally excellent paper of Ferrari et al. (2004). For example, they consider
a two-day fish embryo test as providing acute toxicity data, whereas a
ten-day fish embryo test provides chronic toxicity data. In both cases
the same endpoint, namely mortality, was utilised. But the same paper
also demonstrates that the duration of the test cannot necessarily be
used as the differentiator, because a 96-hour alga test can be considered
both acute (if the EC50 value is the parameter obtained) or chronic (if
the NOEC value is the parameter obtained). Because we did not want
to make the decisions on whether a test was acute or chronic, we
have not separated the toxicity data along those lines.
Another potential strategy would have been to utilise NOEC values
in our assessment of toxicity. However, only 8 out of the 98 papers deal-
ing with effects of propranolol provided NOECs. In total, those 8 papers
provided 17 NOECs, 6 of which came from just one paper (Ferrari et al.,
2004). In contrast, 68 EC50 values were available, thus providing a
much larger dataset, and hence we chose to use that dataset. There
were 13 examples where both an EC50 and a NOEC were provided
from the same test. Based on this limited dataset, the median EC50:
NOEC ratio was 6.4. That is, the NOEC was lower than the EC50 by 6.4-
fold.
Given that by far the largest dataset was based on EC50s, and our
strong desire not to bias our analysis by us conducting further analysis
on the published information (for example, by us trying to determine
NOECs based on the published information), we chose to use EC50
values in our analysis. The limitations of doing so are discussed later in
the paper.
Sixty-eight independent EC50 values for 35 species, covering a wide
range of endpoints, were available (Table S7), and these were used to
construct an SSD (Fig. 1). The species represented in the SSD include
algae (both freshwater and marine), higher plants, bacteria, a variety
of invertebrates (including ciliates, rotifers, crustaceans, echinoderms,
insects and planarians) and fish. For some species more than one,
independently-derived, EC50 value was available. For example, four
EC50 values were available for the green algae Raphidocelis subcapitata,
five for the duckweed Lemnaminor, and eleven for the crustaceanDaph-
nia magna, enabling intra-species sensitivity values to be obtained for
some species. In the case of Daphnia magna, the EC50 values for immo-
bilisation ranged from 0.46 to 18.1 mg/L, a 39-fold difference.
Most EC50 values, irrespective of the species, were in the low mg/L
range. No particular species, or group of species, were significantly
more sensitive than any others. For example, algae were of comparable
sensitivity to Daphnia and other invertebrates. The lowest EC50 value
was 0.084 mg/L, which was for a marine periphyton community. The
SSD provided an HC50 value of 6.64 mg/L (95% confidence intervals
4.38 and 10.08mg/L) and anHC5 value of 0.22mg/L (95% confidence in-
tervals 0.1 and 0.39 mg/L).
The spread of EC50 values can be more easily visualized in Fig. 2.
They cover a range greater than 50,000-fold.
Fig. 1. A species sensitivity distribution (SSD) in mg/L for propranolol based on all acute and chronic EC50 values identified in this study.
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and hence the degree of overlap - if any, of course - between concentra-
tions in rivers and those causing effects can be readily observed. In this
case it is clear that there is no overlap between environmental concentra-
tions and effect concentrations (here represented by the EC50 values). In
fact there is an almost 1000-fold difference between the highest median
river concentration (89 ng/L) and the lowest EC50 concentration (0.084
mg/L). This very significant gap is most clearly displayed in Fig. 3, in
which cumulative frequency distributions of both river concentrations
and EC50 effect concentrations are plotted. Even if an assessment factor
of 1000 was applied by a regulator, thus producing a very small degree
of overlap between effect concentrations and river concentrations (just
one EC50 value out of 68 would be lower than the highest median river
concentration), this still does not imply risk.Fig. 2. A comparison of literature EC50 concentrations for propranolol (blue diamonds; left-ha
column). The median values are plotted as black dashes. (For interpretation of the references t
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As stated in the Methods and Materials, nearly half of the papers
reporting effects of propranolol on aquatic organisms did not provide
an EC50 value, nor could one be calculated or estimated from the pub-
lished information. In many cases this was because only one, or two,
concentrations were tested, rather than a full concentration-response
curve being obtained. When these data are added to the EC50 effect
data, to obtain a complete set of effect data, a different picture emerges.
Fig. 4 shows that the spread of the non-EC50 values was extremely
large, ranging from 0.3 ng/L (3 independent studies, albeit all from the
same research group) to over 100 mg/L. The most noticeable factor,
however, is that a considerable number of non-EC50 values are lower
than any of the EC50 values, often verymarkedly lower. Eleven separate
studies report effect concentrations below 1 μg/L. The species reported
to respond to concentrations of propranolol in the ng/L range includend column) with measured river concentrations of propranolol (red squares; right-hand
o colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3.Cumulative frequency distributions of the EC50 concentrations for propranolol (blue diamonds) andmeasured river concentrations of propranolol (red squares). (For interpretation
of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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wide range of endpoints being reported.
The inclusion of the non-EC50 data leads to an overlap of the river
concentrations and the effect concentrations (Fig. 5A). Put another
way, effects of propranolol on some species have been reported to
occur at concentrations of propranolol present in some rivers. This con-
sequence of including all effect data (EC50 and non-EC50) is most
clearly observed in Fig. 5B, in which separate cumulative frequency dis-
tributions for the EC50 values and the non-EC50 values are shown. Only
the non-EC50 effect concentrations provide any overlap with the me-
dian river concentrations. Around 20% of the non-EC50 values overlap
with propranolol concentrations in rivers.
3.3. River concentrations of propranolol reported in recent publications
In general, recent studies reported lower LOQ levels than older stud-
ies. They also often involved larger sampling campaigns and report
more ‘raw’ data, often in Supplementary Information. Data from many
countries (Egypt, Sri Lanka, China, Spain, Wales, Mexico, Slovenia, andFig. 4.A comparison of all concentrations of propranolol reported to cause an effect (left-hand c
river concentrations of propranolol (right-hand column; red squares). The median values are p
the reader is referred to the web version of this article.)
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England) were collected. Most papers reported significant proportions
of samples having non-detectable propranolol concentrations, even
studies in which the LOQ was lower than 0.5 ng/L. In a comprehensive
study of water quality in small, rural and effluent-dominated streams
and rivers in northeast Spain, it was reported that all samples taken up-
stream of any wastewater entry point had non-detectable propranolol
concentrations (<LOQ of 0.26 ng/L), whereas downstream water sam-
ples had concentrations ranging from <LOQ to 5.44 ng/L (Mandaric
et al., 2018). The median concentration of the samples containing de-
tectable propranolol concentrations was 3.77 ng/L. However, a much
more representative median concentration would be below the LOQ
value of 0.26 ng/L, because 24 of the 33 water samples collected down-
stream of wastewater entry points had concentrations at or below the
LOQ.
Similarly, a comprehensive nationwide study of pharmaceuticals in
streams in China reported a median propranolol concentration below
the LOQ of 0.2 ng/L (Yao et al., 2018). In that study the mean concentra-
tion was reported to be 0.25 ng/L and the maximum concentration was
3.1 ng/L.olumns; EC50 values in blue diamonds, non-EC values in purple diamonds)withmeasured
lotted as black dashes. (For interpretation of the references to colour in this figure legend,
Fig. 5. Cumulative frequency distributions of all concentrations of propranolol reported to cause an effect (right-hand distributions) andmeasured river concentrations of propranolol (red
squares). Panel A shows all effect data (EC50 values in blue diamonds, non-EC50 values in purple diamonds) combined into a single frequency distribution, whereas Panel B shows
separately the EC50 values (black diamonds) and non-EC50 values (purple diamonds) as two separate frequency distributions, as well as the frequency distribution based on the
combined dataset. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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theUK. InWales, an average concentration of 20.6+/− 3.5 ng/Lwas re-
ported (Proctor et al., 2019) and in England the range was reported to
be <5 to 67 ng/L (White et al., 2019).
4. Discussion
4.1. Collection of data
Large amounts of data for both concentrations of propranolol in riv-
ers and lakes and concentrations of propranolol reported to cause ef-
fects to aquatic organisms were available. Despite the fact that it is
very likely that some of the source papers contained errors, and equally
likely that we introduced errors when we extracted the data required
and entered them onto spreadsheets, the quantity of data available
probably largely negated any problems, allowingus to reach reliable, ro-
bust conclusions free of significant bias. To provide just one example of
the errorswe found in published papers, the otherwise excellent review
by Fent and colleagues (Fent et al., 2006) contains an error in the re-
ported concentrations of propranolol. Whereas Roberts and Thomas
(2006) report both influent and effluent propranolol concentrations to
be in the ng/L range, their values are reported in Table 2 of Fent et al.7
(2006) to be in μgs/L. Hence a concentration of 304 ng/L became a con-
centration of 304 μg/L. Fortunately, Fent et al. (2006) did not repeat this
error in their figures, or in their calculations of the median propranolol
concentration. Thus a very comprehensive, thoughtful and important
review was not adversely affected by this simple, easy-to-make error.
It is inevitable that our literature searches failed to locate some rele-
vant papers, although we consider that the number of relevant papers
unintentionally omitted is likely to be low, and hence their inclusion
would probably have had little, if any, significant impact on our
conclusions.
4.2. Concentrations of propranolol in rivers
In general, there was a high degree of consistency of reported pro-
pranolol concentrations in rivers, which provides a great deal of confi-
dence in the data. Measured concentrations of propranolol in rivers
were in the low ng/L range, or even lower, irrespective of the river
(large or small), the country, or the analytical methodology employed
to measure those concentrations. In fact the median concentration we
obtained of 7.1 ng/L is very likely to be an over-estimate of the true rep-
resentative concentration, mainly as a consequence of the issues
outlined in the Materials and Methods. The most important issue was
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appeared that the median (or mean) concentration provided in a
paper was the median only of the river water samples that had quanti-
fiable propranolol concentrations. If all samples that had limit of detec-
tion (LOD) or LOQ propranolol concentrations had been included when
authors reported their data, then it is probable that our calculated over-
all median concentration of 7.1 ng/Lwould have been lower, possibly by
an appreciable amount. However, we sympathise with authors present-
ing concentration data because there is no generally acceptedway of ar-
riving at a median (or mean) concentration when some samples have
either no detectable target analyte or concentrations that cannot be
quantified accurately (Hites, 2019). We applaud some authors who
carefully described how their median propranolol concentrations
were derived (see, for example, Guruge et al., 2019).
Drugmanufacturing can lead to pollution ‘hot spots’where environ-
mental concentrations of pharmaceuticals can be very much higher
than typical representative concentrations (Larsson, 2014). However,
we are not aware that any propranolol ‘hot spot’ has been identified,
leading us to conclude that it seems unlikely, based on current knowl-
edge, that any aquatic environment has a propranolol concentration
above the ng/L range identified here as representative.
Although we did not conduct a thorough review of the literature
published after we conducted our extensive literature searches in
early 2017, the recent literature that we did select provided a tentative
indication that reported propranolol concentrations in rivers may be
lower now than they were in earlier years. There are at least three pos-
sible explanations for why this might be the case. One is that steady im-
provements in analytical techniques often lead to lower concentrations
being determined, as problems (e.g. matrix effects) are better under-
stood and minimised or even eliminated. Another is that the medical
use of propranolol might be decreasing as it is replaced bymore specific
beta-blockers, such as metoprolol and atenolol. The third is that steady
improvements in wastewater treatment will be leading to higher re-
moval rates of micropollutants such as propranolol, hence there should
be lower concentrations in effluents discharged into rivers.
4.3. Concentrations of propranolol reported to cause effects to aquatic
organisms
If only EC50 values obtained from usually standardised tests proto-
cols in which full concentration-response relationships were consid-
ered, then there was a fairly high degree of consistency in the
concentrations reported to cause effects on aquatic organisms. Most
EC50 values were in the low to medium mg/L range with, perhaps sur-
prisingly, no evidence that chronic values were lower than acute values,
as might have been expected. This relative consistency in EC50 values
led to the SSD being reasonably steep, and providing no convincing ev-
idence that one group of organisms was significantly more sensitive to
propranolol than other groups of organisms. This is true for both acute
and chronic toxicity data. A similar conclusion was reported recently
by Damasceno de Oliveira et al. (2018), who provided an SSD for pro-
pranolol based on a smaller, albeit similar, dataset to ours (they used
20 EC50 values from 18 species). In both cases the median effect con-
centration is in the low mg/L range (our SSD provided an HC50 of
6.64 mg/L). Little apparent difference between acute and chronic effect
concentrations provides an interesting outcome of this global compari-
son of reported effects, and not one we would might have predicted for
a compound with a wide safety range in humans. Perhaps this is a re-
flection of the homogenisation of data points where we combine the
EC50s without differentiating the endpoints, as is the accepted method
for generating an SSD. Ferrari et al. (2004) did separate their toxicity
data for propranolol into acute and chronic. They showed that the
chronic data were about 25-fold lower (our estimate from their figure)
than the acute data. This difference would not appreciably affect our
conclusion that propranolol poses little or no risk to aquatic organisms,
because we report that there was nearly a million-fold difference8
between the HC50 obtained from our SSD and themedian river concen-
tration. A detailed discussion of the use of both acute and chronic toxic-
ity data in the environmental risk assessment of pharmaceuticals can be
found in Vestel et al. (2016). Based on a reasonably large dataset, they
show that, once the recommended safety assessment factors are applied
(1000 for acute toxicity data; 10 or 50 for chronic toxicity data), PNECs
derived from acute data “were lower than the PNECs derived from
chronic data”. Thus, they argue that acute toxicity data can be used
with confidence in environmental risk assessment.
The mg/L range of most EC50s also points towards non-specific tox-
icity (narcosis) rather than specific mode of action driven effects that
might be expected for a compound designed to induce specific biologi-
cal effect in humans. Crucially, we see no particular pattern of species
sensitivity in the distribution (Fig. 1). Previously, our focus has been
on the concentration within an organism causing the effect rather
than the concentration in the water. We worked on the hypothesis of
better predicting environmental toxicity of pharmaceuticals on the
basis that internal concentration within an aquatic organism is the key
for comparison with the pharmacological effect in humans. That is, we
might reasonably expect effects at the same concentrations inside a
fish as those in circulating blood plasma of a human (Rand-Weaver
et al., 2013). That hypothesis provides a framework to make a reason-
able worst case estimate of what effects one might predict if aquatic
animals have the physiology and receptor systems comparable to
humans. But to datewehave little evidence for the assumption of equiv-
alent sensitivity in aquatic life as occurs in mammals. Gunnarsson and
workers (2019) examined all the available regulatory data for effects
of pharmaceuticals in aquatic life (fish, invertebrates and algae). They
concluded that when the targets are conserved only in fish, then they
are likely the most sensitive species, but when pharmacological targets
are conserved across phyla we should continue to test the three trophic
levels of fish, invertebrates and algae. We can look at propranolol phar-
macological targets across a range of phyla using a tool developed by
that same group (ECOdrug; www.ecodrug.org; Verbruggen et al.,
2017). Currently the annotation of adrenergic receptors suggests only
chordates likely have the adrenergic receptors -beta-1, beta-2, beta-3
(ADRB1/ADRB2/ADRB3) andwewould expect these to be themost sen-
sitive. This is notwhatwe see from the present study. Indeed it is the in-
vertebrates and algae that appear to be some of the more sensitive
species, despite apparent lack of target.We suggest that atmg/L concen-
trations in the water, these literature studies are effectively reporting a
generalised narcosis response, and this toxicity is not differentiated by
presence or absence of receptors, and thus EC50 data tells us little
about the relative sensitivities in adrenergic blockade in wildlife.
However, the non-EC50 data tell a very different story. The range of
concentrations reported to cause effects - any significant effect in any
aquatic organism - is now very wide, varying from 0.3 ng/L to over
100 mg/L, with many papers reporting effects occurring at concentra-
tions below any EC50 values. Of course, the toxicity tests providing
EC50 values also demonstrate that effects occurred at lower concentra-
tions than those EC50 values. For example, the EC5 value is often around
10% of the EC50 value, so if an EC50 value was 1 mg/L, then an effect
equivalent to 5% of the maximum – but still an effect – would occur at
0.1 mg/L. It is perhaps not surprising that the range of concentrations
causing effects is fairly wide when all molecular, biochemical, physio-
logical and apical endpoints are included in the analysis. The apical end-
points that are the basis for most OECD ecotoxicity tests are likely to be
somewhat less sensitive than molecular and biochemical endpoints in
particular. Inclusion of these data has a dramatic effect on any conclu-
sions regarding the environmental risk posed by propranolol (see
later). There were many different reasons why these papers did not
report an EC50 value, including the following:
1: Only one concentration was tested.
2: Many concentrationswere tested, but only the highest one produced
an effect, allowing a LOEC, but not an EC50 value, to be determined.
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nitude of effect. That is, there was no concentration-response.
4: Many concentrations were tested, but no sigmoidal concentration-
related response relationship occurred. Instead, the response rela-
tionship varied in shape; for example, being an invertedU-shape (in-
termediate concentrations only caused effects).
5: An EC50 value probably could have been obtained from the data, but
one was not reported (and could not be calculated by us).
Eleven papers reported effects occurring in the ng/L range, with the
lowest effect concentration being 0.3 ng/L. Two research groups contrib-
uted four papers each to this collection of eleven papers. In none of these
eleven papers was a sigmoidal concentration-response reported. In two
of them only one concentration of propranolol was tested (Franzellitti
et al., 2013, 2015), hence no concentration-response information was
provided, and in the other nine papers, all of which involved testing 3
or more concentrations of propranolol, non-sigmoidal concentration-
response relationships were reported (e.g. Finn et al., 2012; Maranho
et al., 2015; Maranho et al., 2014), varying from U-shaped and inverted
U-shaped concentration responses (e.g. Finn et al., 2012; Franzellitti
et al., 2011; Maranho et al., 2015) to all concentrations causing similar
degrees of apparent effect that were significantly different from the
controls but not from each other (e.g. Finn et al., 2012; Franzellitti
et al., 2011; Maranho et al., 2015).
It is impossible to knowhow repeatable these ‘low concentration’ ef-
fects are. It is extremely unusual for published ecotoxicology results,
even surprising ones, to be repeated, although Franzellitti and col-
leagues do appear to have shown that some of their ‘low concentration’
effects are repeatable (compare, for example, the results in Franzellitti
et al., 2011 and Franzellitti et al., 2013). It is even more unusual for
ecotoxicologists to demonstrate that surprising results, such as effects
occurring at very low concentrations, cannot be repeated. Even when
authors describe their own published results as surprising, they appear
not to have assessed their repeatability. However, Owen et al. (2010)
did test the issue of repeatability of surprising results in the case of a dif-
ferent pharmaceutical, clofibric acid. They showed that in one experi-
ment all tested concentrations, including very low ones, apparently
caused significant effects, whereas in a repeat experiment, utilising a
more robust experimental design, only the very highest concentration
caused any effects. A very vigorous scientific debate has been ongoing
for more than two decades on the repeatability, or otherwise, of so-
called ‘low dose’ effects, with some scientists believing strongly in
such effects (see the review by Vandenberg et al., 2012), whereas
other scientists equally strongly do not (e.g. Rhomberg and Goodman,
2012). Our personal opinion is that we remain sceptical of the repeat-
ability of the reported ‘low concentration’ effects of propranolol on var-
ious aquatic organisms, and will remain so until they are shown to be
repeatable based on robust experiments conducted by independent re-
search groups. To their credit, and importantly, Franzellitti and col-
leagues state that the effects they observed did not appear to result in
any obvious detrimental effects on their experimental animals (e.g.
Franzellitti et al., 2011).
A number of authors have argued that the ecotoxicology of propran-
olol, or any pharmaceutical for thatmatter, should be based on themode-
of-action (MoA) of the drug (e.g. Franzellitti et al., 2013; Gunnarsson
et al., 2008; Owen et al., 2007; Rand-Weaver et al., 2013). It is therefore
somewhat ironic that relatively few ecotoxicological studies appear to
have utilised the clinically important effects of propranolol, which are re-
duced heart rate and lower arterial blood pressure, as endpoints. Out of
all the papers we reviewed reporting effects of propranolol, only five
assessed heart rate as an endpoint and none assessed arterial blood pres-
sure. Our literature search found only one specific ecotoxicological paper
(as opposed to the many comparative physiology papers) that investi-
gated the effects of propranolol on the heart rate of adult fish. In that
paper (Larsson et al., 2006) the authors concluded “During a 48h expo-
sure .... to a very high concentration of propranolol (70.9 μg/L) no effects9
onheart ratewere found”. Investigating potential effects on the heart rate
of fish embryos/larvae is technically easier, and this strategy has been
employed in a few studies, although consistent results have not been
obtained. Fraysse et al. (2006) obtained a clear concentration-response
relationship when they exposed 4 day-old zebrafish larvae to proprano-
lol. The lowest concentration having a significant effectwas 27 μM(about
7 mg/L). In contrast, no consistent effect on heart rate was obtained by
Mitchell and Moon (2016) when they tested concentrations up to
20 mg/L. Much lower concentrations, in the μg/L range, were tested by
Finn et al. (2012), who reported no effect on the heart rate of either
Japanese Medaka or Zebrafish embryos when they were directly ex-
posed, but reduced heart rate of embryos of both species if their parents
had also been exposed to the drug. A concentration as low as 0.09 μg/L
appeared to cause a significant reduction. However, all 3 concentrations
tested were reported to cause the same degree of decrease in heart
rate. It would be extremely helpful to the environmental risk assessment
of propranolol, or any other beta-blocker, if consistent, reproducible,
concentration-related MoA effects, such as those on the cardiovascular
system, were available. However, this is apparently equally difficult to
do even within the mammalian experimental literature. Margiotta-
Casaluci et al. (2019) conducted ameta-analysis of the effects of propran-
olol (and two other cardiovascular drugs) in the literature and found that
both the degree of pharmacological effect and the direction of that effect
(increase or decrease) varied widely across human, dog, rat, mouse and
zebrafish studies. They also demonstrated an apparent dose-response re-
duction in heart rate from 16 to 125 μM over an hour exposure and sim-
ilarly depressed heart rate and reduced blood flow at 16 μM after 48 h
exposure. Since fish have a low pressure circulatory system, further re-
duced pressure is difficult to measure and may be one reason this end-
point was not measured in fish physiological studies using propranolol,
but perhaps blood flow is a surrogate? There is little doubt that propran-
olol can cause the anticipated MoA effects, because the drug has been
widely used for decades by comparative physiologists studying the role
of the adrenergic nervous system in regulating the heart of fish in partic-
ular, but also other species. For example, Steele et al. (2011) used 10−4
Molar propranolol (about 26 mg/L) to produce a 25% decrease in heart
rate of larval zebrafish. It would be extremely useful if a few well-
designed, well-conducted studies with fish, or fish tissue or even fish
cells, could be conducted, incorporating appropriate MoA endpoints, in
order to establish if those chronic studies do, or do not, reveal that they
are the most sensitive toxicity tests. The results of such studies could
then be used to assess the suitability of the SSDmethodology. The results
of such studieswould also test our conclusion that current concentrations
of propranolol in rivers pose no risk to aquatic organisms.
In a paper specifically focussed on MoA effects of propranolol on an
invertebrate, the crustacean Daphnia magna, Jeong et al. (2018) report
that the drug affected a number of behavioural and physiological end-
points, but no concentration-related responses were obtained; instead,
all concentrations apparently caused effects of similar magnitude. De-
spite this, the authors concluded that the MoA of propranolol “was re-
vealed to be not baseline toxicity but heart specific”. Determining
whether or not all the effects of propranolol on both vertebrates and in-
vertebrates are MoA driven, and hence could be predicted if the physi-
ological roles of the adrenergic system are known, should be a high
priority if predictive ecotoxicology is to become a reality (as also sug-
gested by Zhang et al., 2020).
4.4. Comparison of river concentrations of propranolol with concentrations
reported to cause effects to aquatic organisms
Based on a comparison of all reported concentrations of propranolol
in the freshwater environment (median concentration of 7.1 ng/L;
highest individual sample concentration 590 ng/L) and all reported
EC50 values (lowest value 0.084 mg/L in a non-standard test based on
marine periphyton communities; lowest with a freshwater species
0.132 mg/L; Table S7), there is a very large gap between the two. The
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HC50 value from a SSD of 6.64 mg/L is nearly six orders of magnitude
(i.e., nearly one million-fold). However, there are very important ca-
veats relevant to this comparison. One is that the endpoint in well
over half of the toxicity tests that provided EC50 values was death (or
immobilisation), which is probably a relatively insensitive endpoint.
As stated above, reliance solely on EC50 values obscures the fact that
the same tests that provided those values also demonstrate that some
test organisms died when exposed to lower concentrations. The other
is that non-lethal effects (e.g., molecular, biochemical) are very likely
to occur at lower concentrations than the EC50 values. But even if ro-
bust, repeatable, non-lethal effects could be demonstrated to occur at
concentrations one thousand-fold lower than the median EC50 value,
there would still be a difference of nearly 1000-fold between the two
concentrations.
Only when the non-EC50 effect data are included is there any over-
lap between propranolol concentrations in rivers and those reported to
cause effects on aquatic organisms. Thus, it is possible that environmen-
tal concentrations of propranolol are high enough to cause effects to at
least some aquatic organisms. However, this conclusion depends
completely on whether or not the ‘low effect’ data are repeatable: data
thatwe are sceptical about. In our opinion, the vastmajority of the avail-
able data demonstrate that existing concentrations of propranolol in the
freshwater environment present no risk to aquatic organisms. A similar
conclusion was reached by Huggett et al. (2002) nearly two decades ago,
although theybased their opinionon results fromtests using invertebrates
only. In contrast, Zhang et al. (2020) concluded that propranolol “may
pose an environmental risk”. They reached their conclusion, which they
admirably term ‘tentative’, because they accepted and incorporated data
into their risk assessment, in particular some of the low-concentration
effect data from mussels (e.g. Franzellitti et al., 2011), that we consider
potentially problematic.
Regarding other beta-blockers in worldwide use, such as atenolol
and metoprolol, significantly less has been reported in the scientific lit-
erature about their environmental presence and potential impact on
aquatic organisms compared to propranolol. Nevertheless, it seems
clear that they pose an even lower threat to the environment than pro-
pranolol does. This is a consequence both of their lower toxicity and
greater ease of degradation (e.g. Aydin et al., 2017; Zhang et al., 2020).
4.5. General, important issues
4.5.1. Why was propranolol considered a significant environmental risk?
One of thefirst challenges for environmental scientists ought to be to
think hard about which chemical, or group of chemicals, to focus their
research on: that should be the chemicals that pose the greatest risk
(Johnson et al., 2017). Yet surprisingly, no authors stated explicitly
why they focussed on propranolol. No authors developed a logical argu-
ment as to why propranolol might present an environmental risk to
aquatic organisms, and hence merited study. In contrast, logical argu-
ments were developed to suggest that steroidal pharmaceuticals
might pose a risk to fish in particular (Runnalls et al., 2010); arguments
that proved to be correct (Donnachie et al., 2016; Gunnarsson et al.,
2019).
In a thoughtful paper, Roos et al. (2012) compared nine different
strategies for prioritising pharmaceuticals for the degree of environ-
mental risk they might pose. Propranolol featured in the top ten phar-
maceuticals in three of these strategies, including being number 1 in
the ranking based on measured environmental concentrations divided
by the predicted no effect concentration (MEC/PNEC). Donnachie et al.
(2016) explicitly questioned the rationale for selecting certain pharma-
ceuticals for study, as well as questioning the need to focus on pharma-
ceuticals as opposed to other chemicals, such as metals. They identified
22 research papers providing prioritization schemes for pharmaceuti-
cals, and used the frequency of pharmaceuticals appearing in these
lists to select a ‘top 12’ pharmaceuticals. Propranolol was one of the10most cited pharmaceuticals. Yet when Donnachie et al. (2016) com-
pared reported environmental concentrations with concentrations re-
ported to cause effects on aquatic organisms, they found that the two
median values were more than 100,000-fold apart; that is, the median
environmental concentration was over 5 orders of magnitude lower
than themedian concentration reported to cause an effect on an aquatic
species. In this paper we very significantly expand the database used by
Donnachie and her co-workers (Donnachie et al., 2016), but come to the
same conclusion, although with the caveat that inclusion of the ‘low
concentration’ effect results discussed above raises uncertainties about
the robustness of this conclusion. We consider it likely that the per-
ceptions of many scientists that propranolol posed a significant
degree of risk to aquatic organisms was driven largely by the pop-
ularity of the chemical to environmental scientists (both chemists
and ecotoxicologists), and thus is an example of the so-called
Matthew Effect (Daughton, 2014).
We have reached a very different conclusion to that reached by
Ferrari et al. (2004), who concluded that propranolol did pose a risk to
the aquatic environment. In their generally excellent paper, they used
the European Medicines Agency (EMEA) guidelines on how to conduct
environmental risk assessments of human pharmaceuticals to assess
the risks posed by six pharmaceuticals, including propranolol. They re-
port that the PEC:PNEC ratios varied between 0.49 (if acute toxicity
data were used) and 104 (if chronic toxicity data were used). The
main reasons for their conclusion that propranolol probably posed a
risk to the aquatic environment were (1) they used only the highest re-
ported surface water concentration of propranolol, which as we stated
earlier is 590 ng/L, for their exposure concentration, and (2) they ap-
plied an assessment factor of between 10 and 1000, depending on
data availability, to determine the risk ratio. The novelty, and robust-
ness, of our approach is that we used all published surface water con-
centration data, and we did not apply any arbitrary assessment factors
because a large toxicity database was available to us.
4.5.2. Was so much research on propranolol required?
The answer to this question must be no. A much smaller amount of
research, selected intelligently and done to high standards (see
below), would have demonstrated that propranolol constituted a very
small threat, if any threat at all, to aquatic organisms. The highest envi-
ronmental concentrations of propranolol are likely to occur in countries
where the drug is widely prescribed, where population density is high,
and where rivers receive high volumes of wastewater effluents (Keller
et al., 2014). Hence, determining propranolol concentrations in south-
ern England, The Netherlands, and north-east Spain should provide
some of the highest concentrations of propranolol, worldwide, in rivers.
In the case of effects of propranolol on aquatic organisms,
conducting OECD-validated tests on a range of organisms would proba-
bly have provided all the necessary effect concentrations required for an
ERA. In fact some authors did exactly that (e.g. Calleja et al., 1994;
Ferrari et al., 2004; Huggett et al., 2002; Yamamoto et al., 2007), and
they produced very reproducible, consistent results. Hence, no more
than half a dozen papers provide all the effect data required for a robust
risk assessment, based onwidely acceptedmethodology as used by reg-
ulators across the world, to be conducted. However, as these OECD-
validated tests do not have as an endpoint a specific effect based on
the MoA of propranolol (e.g. reduced heart rate), it could be reasonably
argued that a few ecotoxicity studies needed to be conducted based on
the read-across hypothesis (Rand-Weaver et al., 2013; Zhang et al.,
2020). As discussed above, some authors did conduct appropriate stud-
ies, and found no obviously increased risk of propranolol.
4.5.3. How can things be done better in the future?
There is now fairly wide acceptance that the quality of research gen-
erally could, and probably should, be better than it currently is. Ecotox-
icology research is no exception (Harris and Sumpter, 2015; Mebane
et al., 2019). Various suggestions have been put forward covering how
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et al., 2014; Hanson et al., 2017). Althoughwe did not attempt to assess
all the papers we utilised in order to rate their credibility (this would
have been amonumental task), it was obvious to us that a high propor-
tion of those papers, particularly many of those covering potential ef-
fects of propranolol, would not have rated highly. Many did not abide
by the ‘Principles of Sound Ecotoxicology’ (Harris et al., 2014) and
many would have scored poorly based on the CRED reporting criteria
(Moermond et al., 2016) and the similar but wider quality criteria
outlined by Hanson et al. (2017). This finding is, of course, not relevant
only to the risk assessment of propranolol; it is equally relevant to all
ecotoxicology research, irrespective of which chemical, or mixture of
chemicals, is under investigation. The section below provides guidance
on how the relevance (=usefulness) of ecotoxicology research can be
increased.
Most of the research that we based this meta-analysis on was, pre-
sumably, conducted in order to protect the environment fromchemicals
released into it. If research is not conducted to high standards it is of
minimal, or no, use to regulators. If regulators cannot use it to help
them protect the environment, then it is questionable whether that re-
search should have been conducted in the first place. This is particularly
true if that research involved the use of animals. An identical conclusion
was reached independently recently by Constantine et al. (2020), based
on their inability to reproduce some reported ‘low concentration’ effects
of the pharmaceutical ibuprofen: they wrote “Applying Harris, et al
(2014) and Hanson, (2017) recommendations would lead to more reli-
able and relevant ecotoxicity data, thereby increasing stakeholder con-
fidence…etc”.
In order to improve the current situation, scientists need to be
trained better (Harris et al., 2017; Mebane et al., 2019). Much more
thought needs to be devoted to deciding what research to do, then
how to do the research considered the most important and relevant
to protecting the environment from chemicals, including proprano-
lol. Many of the factors that need addressing in order to improve
the quality of both scientists and the research they do are covered
in the book ‘How to be a better scientist’ (Johnson and Sumpter,
2019).
5. Conclusions
Based on the results of many hundreds of research papers, the
median concentration of propranolol in rivers was found to be
7.1 ng/L. The median effect concentration of propranolol based on
ecotoxicity tests from which EC50 values were provided was
6.64 mg/L. Even if robust, non-lethal molecular or biochemical ef-
fects occur at lower concentrations, nevertheless we conclude that
propranolol does not constitute any risk to freshwater organisms.
However, some non-standard ecotoxicity studies have suggested
that very low (ng/L or even sub-ng/L) concentrations of propranolol
can cause a range of effects to some aquatic species. Often these ap-
parent effects were not concentration-related, raising concerns
about the repeatability of those ‘low concentration’ effects. Until
they are demonstrated to be repeatable, we consider that proprano-
lol concentrations in rivers across the world currently pose no risk to
aquatic species.
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